会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • PATIENT-RELATED DATA MANAGEMENT SYSTEM AND METHOD WITHIN THE SCOPE OF AN EVALUATION OPERATION
    • 患者相关数据管理系统和方法在评估操作的范围内
    • US20110270621A1
    • 2011-11-03
    • US12300994
    • 2007-05-15
    • Nicolas GlattAntoine AngenieuxThomas Glatt
    • Nicolas GlattAntoine AngenieuxThomas Glatt
    • G06Q50/00G06Q10/00
    • G06Q50/22G16H10/20G16H10/60G16H40/20
    • Patient-related data management method within the scope of an evaluation operation conducted in at least one treatment centre (100), characterised in that it comprises the steps consisting of the input of data relating to a patient using at least one input terminal (112) to form a patient record, the validation of said input using a patient application (115), the automatic processing of the patient record by the patient application (115) to form a source record which complies with one or more regulatory requirements, the registration of the source record in a source database (10) deployed in the treatment centre (100) taking part in the evaluation operation, the comparison of the source record data with enrollment criteria provided by the sponsor of the evaluation operation, the pre-enrollment of the source record whereby, in particular, the source record is duplicated automatically to form a potential evaluation record, the registration of the potential evaluation record in a local evaluation database (20) deployed in the treatment centre (100), the enrollment of the potential evaluation record using a local evaluation application (121), the validation of this enrollment step resulting in the export of the data from the potential evaluation record to form a CRF evaluation record in compliance with the sponsor's requirements, the registration of the CRF evaluation record in a database (10) deployed in the treatment centre (100).
    • 在至少一个治疗中心(100)中执行的评估操作的范围内的患者相关数据管理方法,其特征在于,其包括由使用至少一个输入终端(112)输入与患者有关的数据的步骤, 形成患者记录,使用患者应用(115)验证所述输入,由患者应用(115)自动处理患者记录以形成符合一个或多个监管要求的源记录,注册 部署在治疗中心(100)的源数据库(10)中的来源记录参与评估操作,源记录数据与评估操作的赞助者提供的注册标准的比较,预注册 源记录,特别是源记录自动复制以形成潜在的评估记录,将潜在评估记录注册到本地ev 部署在治疗中心(100)的评估数据库(20),使用本地评估应用程序(121)注册潜在评估记录,验证该注册步骤,导致从潜在评估记录导出数据以形成 符合发起人要求的CRF评估记录,CRF评估记录在部署在治疗中心(100)的数据库(10)中的注册。
    • 4. 发明授权
    • Polymeric acetal resins containing free radical inhibitors and their use in lithographic printing
    • 含有自由基抑制剂的聚合缩醛树脂及其在平版印刷中的应用
    • US06783913B2
    • 2004-08-31
    • US10117505
    • 2002-04-05
    • Hans-Horst GlattUdo DwarsHarald BaumannIngrid Glatt
    • Hans-Horst GlattUdo DwarsHarald BaumannIngrid Glatt
    • G03F70021
    • C08F8/00C08F216/06
    • Polymeric acetal resins useful in lithographic printing are disclosed. The polymeric acetal resin contains units (A), (B), (C), (D), and (E). Unit (A) is a vinyl alcohol unit. Unit; (B) is a polyvinyl acetal unit containing an R group, where R is hydrogen, an aliphatic group, an aromatic group, or an arylaliphatic group. Unit (C) is a vinyl carboxylate unit. Unit (D) is an acidic vinyl acetal unit and/or a residue of an acidic vinyl monomer. Unit (E) is a free radical polymerization-inhibiting vinyl acetal unit and/or a free radical polymerization-inhibiting vinyl alcohol ester unit. The resin comprises about 10 to about 60 mol % of unit (A), about 5 to about 60 mol % of unit (B), about 0.3 to about 30 mol % of unit (C), about 1 to about 40 mol % of unit (D), and about 0.01 to about 2 mol % of unit (E).
    • 公开了可用于平版印刷的聚合缩醛树脂。 聚合缩醛树脂含有单元(A),(B),(C),(D)和(E)。 单元(A)是乙烯醇单元。 单元; (B)是含有R基团的聚乙烯醇缩醛单元,其中R是氢,脂族基团,芳族基团或芳基脂族基团。 单元(C)是羧酸乙烯酯单元。 单元(D)是酸性乙烯基缩醛单元和/或酸性乙烯基单体的残基。 单元(E)是一种自由基聚合抑制乙烯基缩醛单元和/或自由基聚合抑制乙烯醇酯单元。 树脂包含约10至约60mol%的单元(A),约5至约60mol%的单元(B),约0.3至约30mol%的单元(C),约1至约40mol%的单元 单位(D)和约0.01至约2摩尔%的单元(E)。